<DOC>
	<DOCNO>NCT00972855</DOCNO>
	<brief_summary>The objective study compare rate extent absorption bicalutamide 50 mg tablet ( test ) versus Casodex® ( reference ) administer 1 x 50 mg tablet feed condition .</brief_summary>
	<brief_title>Study Bicalutamide 1 x 50 mg Tablet Healthy Subjects Under Fed Conditions</brief_title>
	<detailed_description>This single center , bioequivalence , open-label , randomized 1-way parallel study . According BA/BE guidance , parallel study acceptable drug long half-life .</detailed_description>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Subjects male , nonsmoker , 18 year age old . Subjects follow applies exclude study : Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 ; heart rate le 50 bpm ) screening . Subjects BMI ≥30.0 . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . History allergic reaction bicalutamide relate drug . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigation study within 30 day prior administration study medication . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Any food allergy , intolerance , restriction special diet could , opinion medical subinvestigator , contraindicate subject participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : Less 300 mL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . Positive alcohol breath test screening . Subjects use tobacco form within 90 day precede study drug administration . Subjects clinically significant history tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
</DOC>